Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: Where we stand

American Journal of Gastroenterology

Volumn 91, Issue 10, 1996, Pages 2080-2086

  Graham, David Y ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CIMETIDINE; ETODOLAC; IBUPROFEN; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG SAFETY; HELICOBACTER PYLORI; HUMAN; PAIN; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; ULCEROGENESIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CYCLOOXYGENASE INHIBITORS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MISOPROSTOL; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION; UNITED STATES;

EID: 0029840060     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Graham DY. Evolution of concepts regarding Helicobacter pylori: From a cause of gastritis to a public health problem. Am J Gastroenterol 1994;89:469-72.
2. Soll AH. Gastric, duodenal, and stress ulcer. In: Sleisenger M, Fordtran J, eds. Gastrointestinal disease, 5th ed. Philadelphia: WB Saunders, 1993: 580-679.
3. Go MF, Graham DY. How does Helicobacter pylori cause duodenal ulcer disease: The bug, the host, or both? J Gastroenterol Hepatol 1994;9(Suppl 1):S8-10.
4. Lee A. Future research in peptic ulcer disease. Scand J Gastroenterol 1994;205(Suppl):51-8.
5. Czinn SJ, Cai A, Nedrud JG. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 1993;11:637-42.
6. Rappuoli R, Covacci A, Ghiara P, et al. Pathogenesis of Helicobacter pylori and perspectives of vaccine development against an emerging pathogen. Behring Inst Mitt 1994;42-8.
7. Peura DA, Graham DY. Helicobacter pylori: Consensus reached: Peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol 1994;89:1137-9.
8. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1985;28:686-92.
9. Anti-arthritic medication usage. United States, 1991. Stat Bull Metrop Insur Co 1992;73:25-34.
10. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075-8.
11. Collins AJ, Davies J, Dixon AS. A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract in patients with osteoarthritis. Br J Rheumatol 1988;27:106-9.
12. Gabriel SE, Bombardier C. NSAID-induced ulcers. An emerging epidemic? J Rheumatol 1990;17:1-4.
13. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol 1992;92(Suppl):21-4.
14. Janssen M, Dijkmans BA, Vandenbroucke JP, et al. Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 1994;39:362-5.
15. Battaglia G, Di Mario F, Dotto P, et al. Markers of slow-healing peptic ulcer in the elderly: A study on 1,052 ranitidine-treated patients. Dig Dis Sci 1993;38:1414-21.
16. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers. Gut 1991;32:252-5.
17. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989;96:647-55.
18. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
19. Hallas J, Lauritsen J, Villadsen HD, et al. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding: Identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995;30:438-44.
20. Fries JF, Miller SR, Spitz PW, et al. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990;20(Suppl): 12-9.
21. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-45.
22. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
23. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 1990;12:260-6.
24. Savage RL, Moller PW, Ballantyne CL, et al. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum 1993;36:84-90.
25. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: A meta-analysis. Ann Intern Med 1991;115:787-96.
26. Bollini P, Garcia Rodriguez LA, Perez Gutthann S, et al. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992;152:1289-95.
27. Fries JF. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 28(Suppl):6-10.
28. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
29. Agrawal N. Risk factors for gastrointestinal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs). J Fam Pract 1991;32:619-24.
30. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am J Med 1991;91:213-22.
31. Garcia Rodriguez LA, Walker AM, Perez Gutthann S. Nonsteroidal antiinflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: A cohort study. Epidemiology 1992;3:337-42.
32. Lanza LL, Walker AM, Bortnichak EA, et al. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years: A large health maintenance organization cohort study. Arch Intern Med 1995;155: 1371-7.
33. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993;105:1078-88.
34. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986;104:390-8.
35. Hochain P, Berkelmans I, Czernichow P, et al. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol 1995;7:419-26.
36. Simon LS, Goodman T. NSAID-induced gastrointestinal toxicity. Bull Rheum Dis 1995;44:1-5.
37. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-26.
38. Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastroenterology 1989; 96:675-81.
39. Nobunga M, Graham DY, Saito T, et al. NSAID-induced gastrointestinal damage and its management. J Rheumatol 1993;9:279-92.
40. Graham DY, Smith JL, Holmes GI, et al. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther 1985;38:65-70.
41. Swift GL, Arnold J, Williams GT, et al. A comparison of upper gastrointestinal mucosal damage by standard and delayed-release indomethacin. Aliment Pharmacol Ther 1992;6:717-25.
42. Graham DY. Clinical aspects fo the protective effects of prostaglandins on non-steroidal anti-inflammatory drug-associated mucosal injury. In: Domschke W, Dannann HG, Peskar BM, et al, eds. Prostaglandins and leukotrienes in gastrointestinal diseases. Berlin: Springer-Verlag, 1988: 161-7.
43. Cooper SA. New peripherally acting oral analgesic agents. Annu Rev Pharmacol Toxicol 1983;23:617-47.
44. Brogden RN, Heel RC, Speight TM, et al. Piroxicam: A review of its pharmacological properties and therapeutic efficacy. Drugs 1981;22: 165-87.
45. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995;310:827-30.
46. Hirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994;2:207-23.
47. Ranke C, Creutzig A, Luska G, et al. Dose-dependent side effects of acetylsalicylic acid therapy. Results of a prospective randomized clinical study in patients with peripheral arterial occlusive disease. Med Klin 1993;88:571-6.
48. Oren R, Ligumsky M, Lysy J, et al. Gastro-duodenal injury associated with intake of 100-325 mg aspirin daily. Postgrad Med J 1993;69: 712-4.
49. Leivonen M, Sipponen P, Kivilaakso E. Gastric changes in coronary-operated patients with low-dose aspirin. Scand J Gastroenterol 1992; 27:912-6.
50. Silagy C. Aspirin and the elderly: Current status. Drugs Aging 1993; 3:301-7.
51. Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993;54: 84-9.
52. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992;103:862-9.
53. Cryer B, Feldman M. Effects of nonsteroidal anti-inflammatory drugs on endogenous gastrointestinal prostaglandins and therapeutic strate-gies for prevention and treatment of nonsteroidal anti-inflammatory drug-induced damage. Arch Intern Med 1992;152:1145-55.
54. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-84.
55. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-6.
56. Hoffman W, Nitschke M, Muche J, et al. Reevaluation of the Cottbus reinfarction study with 30 mg aspirin per day 4 years after the end of the study. Prostagland Leukocyte Essent Fatty Acids 1991;42:137-9.
57. McCarthy DM. Mechanisms of mucosal injury and healing: The role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1995; 208(Suppl):24-9.
58. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-34.
59. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153: 2565-71.
60. Trewin VF, Lawrence CJ, Rae SA, et al. Development and use of a gastropathy index for ranking the safety of non-steroidal anti-inflammatory drugs in the elderly. J Clin Pharmacol Ther 1994;19:209-14.
61. Grossman CM. NSAIDs and gut toxicity (letter). Lancet 1994;344:57.
62. Henry D, Lim LL-Y, Garcia Rodrigquz LA, et al. Variability in risk of major upper gastrointestinal complications with individual NSAIDs. Br Med J 1996;312:1563-6.
63. LeLorier J. Patterns of prescription of nonsteroidal antiinflammatory drugs and gastroprotective agents. J Rheumatol 1995;43(Suppl):26-7.
64. Lanza FL, Karlin DA, Yee JP. A double-blind, placebo-controlled endoscopic study comparing the mucosal injury seen with orally and parenterally administered nonsteroidal analgesic ketorolac tromethamine at therapeutic and supratherapeutic doses (abstract). Am J Gastroenterol 1987;82:939.
65. Prescribing information for Toradol. Nutley, NJ: Roche Laboratories, 1996.
66. Lanza FL, Royer GL. NSAID-induced gastric ulceration is dose related by weight: An endoscopic study with flurbiprofen. Am J Gastroenterol 1993;88:683-6.
67. Wolfe F. The epidemiology of NSAID-associated gastrointestinal disease. Eur J Rheumatol Inflam 1991;11:12-28.
68. Cocks JR. Perforated peptic ulcer: The changing scene. Dig Dis 1992; 10:10-6.
69. Kirchner JT. Nonsteroidal anti-inflammatory drug use in the elderly: Issues of compliance and safety. J Am Osteopath Assoc 1994;94: 300-4.
70. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
71. Henry D, Robertson J. Nonsteroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales. Gastroenterology 1993;104:1083-91.
72. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988;109:359-63.
73. Silverstein F. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease: An overview. Postgrad Med 1991;89:33-40.
74. Armstrong CP, Whitelaw S. Death from undiagnosed peptic ulcer complications: A continuing challenge. Br J Surg 1988;75:1112-4.
75. Hogan DB, Campbell NR, Crutcher R, et al. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Assoc J 1994;151:315-22.
76. Weinblatt ME. Nonsteroidal anti-inflammatory drug toxicity: Increased risk in the elderly. Scand J Rheumatol 1991;91(Suppl):9-17.
77. Ohmann C, Thon K, Hengels KJ, et al. Incidence and pattern of peptic ulcer bleeding in a defined geographical area. DUSUK Study Group. Scand J Gastroenterol 1992;27:571-81.
78. Cryer B, Redfern JS, Goldschmiedt M, et al. Effect of aging on gastric and duodenal mucosal prostaglandin concentrations in humans. Gastroenterology 1992;102:1118-23.
79. Moller Hansen J, Hallas J, Lauritsen JM, et al. Non-steroidal anti-inflammatory drugs and ulcer complications: A risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996;31:126-30.
80. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: A randomized, controlled trial. Ann Intern Med 1991;115:195-200.
81. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993;119:257-62.
82. Ehsanullah RS, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine. Br Med J 1988;297:1017-21.
83. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34:424-8.
84. Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs [see comments]. Arch Intern Med 1993;153:2449-54.
85. Fennerty MB. Nonsteroidal anti-inflammatory drugs, ulcers, and histamine 2 blockers: The ostrich phenomenon! Arch Intern Med 1993; 153:2411-2.
86. Singh G, Rosen Ramey D, Morfeld D, et al. Gastrointestinal complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis: A prospective observational cohort study. Arch Intern Med 1996;156:1530-6.
87. Gunshefski L, Flancbaum L, Brolin RE, et al. Changing patterns in perforated peptic ulcer disease. Am Surg 1990;56:270-4.
88. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens. Ann Intern Med 1995;123:344-50.
89. Graham JA. Prevention and management of NSAID-induced ulcers. Am Pharmacol 1992;NS32:62-4.
90. Graham DY, Smith JL. Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 1988;83:1081-4.
91. Mann CC, Plummer ML. The aspirin wars money, medicine, and 100 years of rempant competition. New York: Alfred A. Knopf, 1991.
92. Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994;107:173-9.